Merck & Co., Inc. (MRK)
Merck Falls 14% YTD: Time to Buy, Sell or Hold the Stock?
Merck stock is down 14% this year as Keytruda-led growth gets offset by Gardasil weakness and looming patent risks, which cloud the outlook.
Britain defends investment record as Merck scraps labs over pharma environment
Britain defended its record on attracting investment on Thursday after U.S. drugmaker Merck said it was abandoning a new London research centre and a top industry lobby group warned a challenging business environment was hurting the sector.
MRK Posts Cholesterol Drug Data, Focus Shifts Back to Its Pipeline
Merck advances growth with phase III pipeline backed by positive data for its potential first oral PCSK9 inhibitor.
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
MRK's ADC Candidate Gets FDA Breakthrough Therapy Tag for Lung Cancer
Merck's ifinatamab deruxtecan wins FDA Breakthrough Therapy status for treating adults with extensive-stage small cell lung cancer.
Can Keytruda Sustain Merck's Growth Through the Rest of 2025?
MRK banks on Keytruda's soaring sales and new oncology strategies to fuel 2025 growth, even as competition and patent loss loom.
Merck: Buy The Weakness
Merck trades at a single-digit P/E, reflecting underperformance but strong financials and a robust dividend yield near 3.9%. Keytruda's ongoing success and expanded indications drive near-term results, but loss of exclusivity looms in three years. Merck's pipeline and Verona acquisition position it to offset Keytruda revenue loss, with $50B+ mid-2030s opportunity projected.
Merck's Narrowed 2025 Sales View: What it Means After Q2 Results?
MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected to drive a second-half rebound.
Merck Stock Down 4% Since Q2 Results: How to Play the Stock
Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its long-term case.
Why Merck (MRK) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Income Strategy: I'm Buying 2 Elite Mispriced Dividends
In the current tech-heavy market, I explore two compelling value stocks with strong yields and trade at deep discounts to historical valuations. Both have competitive advantages and strong histories of capital returns to shareholders. Both appear to be severely mispriced, offering enterprising investors the opportunity to capture value before the market pendulum swings back.
